In today's world, Cinolazepam has become a topic of increasing interest to people of all ages and backgrounds. From its impact on society to its implications on the global economy, Cinolazepam has generated debate and controversy in various areas. As we delve into this exciting topic, it is crucial to understand its many facets and consider the various perspectives that exist on the matter. In this article, we will explore the different aspects of Cinolazepam, analyzing its influence on the modern world and its potential to shape the future.
Clinical data | |
---|---|
Trade names | Gerodorm |
AHFS/Drugs.com | cinolazepam |
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 90–100% |
Metabolism | Hepatic |
Elimination half-life | 3.8 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H13ClFN3O2 |
Molar mass | 357.77 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Cinolazepam (marketed under the brand name Gerodorm) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. Due to its strong sedative properties, it is primarily used as a hypnotic.
It was patented in 1978 and came into medical use in 1992. Cinolazepam is not approved for sale in the United States or Canada.